Crescent Biopharma (CBIO) Times Interest Earned (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Times Interest Earned of -$0.47 for Q1 2026, up 96.35% year-over-year from -$0.24 in Q1 2025, and up 73.3% quarter-over-quarter from -$1.75 in Q3 2025.
Crescent Biopharma (CBIO) Times Interest Earned (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Times Interest Earned for 14 consecutive years, with -$0.47 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 96.35% year-over-year to -$0.47; the TTM figure through Jun 2026 stood at -$77.1 (down 288.6% YoY), while the FY2025 annual figure was -$10.37, down 2.07% from the prior year.
- Times Interest Earned climbed to -$0.47 in Q1 2026 per CBIO's latest filing, from -$1.75 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$0.47 in Q1 2026 and bottomed at -$55.62 in Q4 2023.
- Historically, Times Interest Earned has averaged -$24.35 across 5 years, with a median of -$19.89 in 2024.
- Annual changes were most pronounced in 2025 — Times Interest Earned sank 363.55% — and 2026, when it jumped 96.35%.
- Crescent Biopharma's Times Interest Earned stood at -$37.98 in 2022, then slumped by 46.44% to -$55.62 in 2023, then soared by 63.72% to -$20.18 in 2024, then jumped by 91.34% to -$1.75 in 2025, then soared by 73.3% to -$0.47 in 2026.
- Business Quant data shows CBIO's Times Interest Earned at -$0.47 in Q1 2026, -$1.75 in Q3 2025, and -$19.6 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.47 |
| Jun 30, 2025 | -0.69 |
| Mar 31, 2025 | -12.79 |
| Dec 31, 2024 | -20.18 |
| Sep 30, 2024 | -2,039.54 |
| Jun 30, 2024 | -22.32 |
| Mar 31, 2024 | -2.76 |
| Dec 31, 2023 | -55.62 |
| Sep 30, 2023 | -14.98 |
| Jun 30, 2023 | -8.61 |
| Mar 31, 2023 | -32.56 |
| Dec 31, 2022 | -37.98 |
| Sep 30, 2022 | -31.52 |
| Jun 30, 2022 | -48.79 |
| Mar 31, 2022 | -53.73 |
| Dec 31, 2021 | -63.86 |
| Sep 30, 2021 | -63.88 |
| Jun 30, 2021 | -53.95 |
| Mar 31, 2021 | -53.64 |
| Dec 31, 2020 | -58.48 |